Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra

Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst main

Lucid Diagnostics NASDAQ: LUCD is positioning its EsoGuard test as a non-invasive tool to identify B

Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physi

Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript

Lucid Diagnostics NASDAQ: LUCD reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tes

Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings cal

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.06 per share versus the Zacks Con

Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory be

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.08) per share which missed the anal

Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage cr

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Compa

Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc.  (Nasd

Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics

Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection po

Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript

Lucid Diagnostics reported Q1 revenue miss. Analyst significant expects revenue growth in 2026/27. R

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra

Maxim Group analyst Anthony Vendetti maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and low

Veris Health progressed commercial expansion and advanced implantable physiological monitor developm

Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript

Lucid Diagnostics NASDAQ: LUCD reported first-quarter 2026 EsoGuard test volume above its pre-Medica

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Con

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.07) per share which beat the analys

Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $4

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly sales of $1.256 million which missed the analyst

Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a like

Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc.  (Nasdaq

Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ --  Lucid Diagnostic

 Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage

Top analysts change outlook on top names, like AA, SSSS, TXN, HQY, LUCD, RPM, PAR, ASRT. Morgan Stan

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which met the analyst

PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diag

PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage,

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra

Lucid Diagnostics Inc. $175,000,000 Common Stock, Preferred Stock, Debt Securities, Warrants and Uni

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which beat the analys

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra

BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.

 Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the